Literature DB >> 30109500

MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.

Maria Luisa Gasparri1,2,3, Zein Mersini Besharat4, Ammad Ahmad Farooqi5, Sumbul Khalid6, Katayoun Taghavi7, Raad Aris Besharat8, Claudia Sabato9,10, Andrea Papadia7, Pierluigi Benedetti Panici8, Michael David Mueller7, Elisabetta Ferretti4,11.   

Abstract

Ovarian cancer is a leading cause of death among gynecologic malignancies. This disappointing prognosis is closely related to intrinsic or acquired resistance to conventional platinum-based chemotherapy, which can affect a third of patients. As such, investigating relevant molecular targets is crucial in the fight against this disease. So far, many mutations involved in ovarian cancer pathogenesis have been identified. Among them, a few pathways were implicated. One such pathway is the P13K/AKT/mTOR with abnormalities found in many cases. This pathway is considered to have an instrumental role in proliferation, migration, invasion and, more recently, in chemotherapy resistance. Many miRNAs have been found to influence P13K/AKT/mTOR pathway with different potential role in tumor genesis and ovarian cancer behaviour. In particular, their biological function was recently investigated as regards chemoresistance, therefore, leading to the identification of potential specific indirect biomarker of platinum sensitivity in ovarian cancer.

Entities:  

Keywords:  MicroRNA; Ovarian cancer; PI3K/AKT/mTOR pathway; Platinum resistance

Mesh:

Substances:

Year:  2018        PMID: 30109500     DOI: 10.1007/s00432-018-2737-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  38 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 2.  Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure.

Authors:  Elke Pogge von Strandmann; Silke Reinartz; Uwe Wager; Rolf Müller
Journal:  Trends Cancer       Date:  2017-01-18

Review 3.  Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.

Authors:  Maria Luisa Gasparri; Assunta Casorelli; Erlisa Bardhi; Aris Raad Besharat; Delia Savone; Ilary Ruscito; Ammad Ahmad Farooqi; Andrea Papadia; Michael David Mueller; Elisabetta Ferretti; Pierluigi Benedetti Panici
Journal:  Tumour Biol       Date:  2017-05

4.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

5.  Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

Authors:  Maurie Markman; Jonathan Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

Review 6.  How do real tumors become resistant to cisplatin?

Authors:  Piet Borst; Sven Rottenberg; Jos Jonkers
Journal:  Cell Cycle       Date:  2008-03-17       Impact factor: 4.534

Review 7.  The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.

Authors:  Zachary C Dobbin; Charles N Landen
Journal:  Int J Mol Sci       Date:  2013-04-15       Impact factor: 5.923

8.  MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.

Authors:  Shaohua Xu; Guang-Bo Fu; Zhen Tao; Jun OuYang; Fanfei Kong; Bing-Hua Jiang; Xiaoping Wan; Ke Chen
Journal:  Oncotarget       Date:  2015-09-22

Review 9.  Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.

Authors:  Robert Cornelison; Danielle C Llaneza; Charles N Landen
Journal:  Int J Mol Sci       Date:  2017-10-18       Impact factor: 5.923

10.  MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.

Authors:  Henan Zhao; Xiaotang Yu; Yanfang Ding; Jinyao Zhao; Guang Wang; Xian Wu; Jiyong Jiang; Chun Peng; Gordon Zhuo Guo; Shiying Cui
Journal:  Oncotarget       Date:  2016-08-16
View more
  16 in total

1.  MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.

Authors:  Yulian Mytsyk; Yuriy Borys; Lesia Tumanovska; Dmytro Stroy; Askold Kucher; Katarina Gazdikova; Luis Rodrigo; Peter Kruzliak; Robert Prosecky; Peter Urdzik; Victor Dosenko
Journal:  Clin Exp Med       Date:  2019-08-22       Impact factor: 3.984

2.  Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.

Authors:  Sicheng Lu; Mengjie Guo; Zhimin Fan; Ying Chen; Xuqin Shi; Chunyan Gu; Ye Yang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].

Authors:  L Shang; W Jiang; J Zhang; W Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

4.  LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.

Authors:  Qiying Yao; Li Zhang; Yuchuan Wang; Junli Liu; Liu Yang; Yingjie Wang
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

5.  MicroRNA-96-3p promotes metastasis of papillary thyroid cancer through targeting SDHB.

Authors:  Xupeng Zhao; Yingjie Li; Yong Zhou
Journal:  Cancer Cell Int       Date:  2019-11-12       Impact factor: 5.722

6.  A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy.

Authors:  Yixin Liu; Zheyang Zhang; Tianhao Li; Xin Li; Sainan Zhang; Ying Li; Wenyuan Zhao; Yunyan Gu; Zheng Guo; Lishuang Qi
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

Review 7.  Marine Anthraquinones: Pharmacological and Toxicological Issues.

Authors:  Giulia Greco; Eleonora Turrini; Elena Catanzaro; Carmela Fimognari
Journal:  Mar Drugs       Date:  2021-05-13       Impact factor: 5.118

8.  NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway.

Authors:  Shanyu Fang; Yuanyuan Luo; Ying Zhang; Houmei Wang; Qianfen Liu; Xinya Li; Tinghe Yu
Journal:  Front Cell Dev Biol       Date:  2021-07-01

9.  Development of Multiscale Transcriptional Regulatory Network in Esophageal Cancer Based on Integrated Analysis.

Authors:  Zihao Xu; Zilong Wu; Jingtao Zhang; Ruihao Zhou; Jiane Wu; Bentong Yu
Journal:  Biomed Res Int       Date:  2020-08-12       Impact factor: 3.411

10.  Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract.

Authors:  Li Han; Xueyun Cao; Zhong Chen; Xiaojuan Guo; Lei Yang; Yubing Zhou; Hua Bian
Journal:  BMC Complement Med Ther       Date:  2020-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.